EyePoint Pharmaceuticals is a pharmaceutical company focused on developing and commercializing therapeutics for patients with eye disorders. Co.'s primary product candidate, EYP-19, is a potential sustained delivery intravitreal anti-VEGF treatment targeting wet age-related macular degeneration. YUTIQ 50 (fluocinolone acetonide intravitreal implant) 0.18 mg for intravitreal injection, is for the treatment of non-infectious uveitis affecting the posterior segment of the eye. DEXYCU® (dexamethasone intraocular suspension) 9%, for intraocular administration, is indicated for the treatment of post-operative ocular inflammation. We show 60 historical shares outstanding datapoints in our EYPT shares outstanding history coverage, used to compute EYPT market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing EYPT market cap history over the course of time is important for investors
interested in comparing EYPT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of EYPT versus a peer is one thing; comparing
EYPT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like EYPT can fluctuate over the course of history.
With this page we aim to empower investors researching EYPT by allowing them to research the EYPT market cap history. |
Free EYPT Email Alerts:
Video: The Importance of Market Cap
